Latest ArticlesReactive oxygen species(ROS) are byproducts of cellular redox metabolism. Excessive ROS can lead to oxidative damage of DNA, proteins and lipids, thereby exacerbating the genetic instability of cancer cells and promoting tumor initiation and progression. Peroxiredoxin 1(PRDX1), a key member of the peroxidase family, plays a pivotal role in maintaining intracellular ROS balance, effectively protecting cells from ROS-induced damage. Simultaneously, PRDX1 acts as a molecular chaperone in various malignancies, exhibiting dual roles in either promoting or inhibiting tumor growth. In recent years, numerous PRDX1-targeting candidate drugs have demonstrated significant antitumor effects both in vitro and in vivo, confirming PRDX1 as a potential target for cancer therapy. This review summarizes recent advances in understanding the mechanisms of PRDX1 as a tumor treatment target, as well as the development of antitumor natural products targeting PRDX1.
Diseases caused by bacterial infections pose a significant threat to human health. In recent years, the overuse of antibiotics has led to the emergence of drug-resistant microorganisms and the development of new bacterial strains. These factors have further exacerbated the threat of bacteria to human health and environmental safety. Consequently, the development of novel antibacterial materials to prevent the emergence of “superbugs” has become a key research focus. Metal-organic framework materials(MOFs) have emerged as star materials in the antibacterial field, owing to their exceptional crystallinity, high porosity, large specific surface area, and facile tunability through modification. However, traditional MOFs also exhibit some shortcomings, such as poor hydrophilicity, long antibacterial cycles, and lack of targeting. To overcome these drawbacks, post-synthetic modification of conventional MOFs has emerged as an important strategy. Based on this, this article summarizes several design approaches for novel MOF-based antimicrobial materials, including modification of MOFs metal nodes, functionalization of organic ligands, surface and pore structure modification, and the formation of composites with other materials. The aim is to provide a reference for the future synthesis of advanced antimicrobial MOFs.
The synthesis process of the antihyperglycemic drug linagliptin(1) was optimized, and the key process parameters for each step were determined, along with the impurities generated. Starting from 8-bromo-7-(but-2-yn-1-yl)-3-methylxanthine(3), crude 1 was obtained through a two-step substitution reaction and deprotection. The pure target 1 was afforded by recrystallization from ethanol with an overall yield of 74.6%(based on 3) and HPLC purity of 99.85%, while individual impurity below 0.05%. By replacing the deprotection reagent with trimethylsilyl trifluoromethanesulfonate(TMSOTf), the process was stabilized and simplified, significantly reducing the formation of the dimer impurity of 1 (namely related substance B). This optimized process was suitable for industrial production. Furthermore, nine related substances were synthesized, among which the synthetic routes of related substances A, C, D, E, F, G, H, and I were reported at the first time. This study is expected to provide a valuable reference for the quality control of 1 .